Abstract:Partial intestinal ischaemia was produced by ligation of selected primary laterals of the mesenteric artery in the rat. Both positively and negatively charged liposomes (multiply labelled with [99mTc]diethylenetriamine pentaacetic acid, [3H]methoxy-inulin, and [4-14C]-cholesterol), administered 24 h following ligation, were accumulated in ischemic (necrotic) intestine.
“…99mTc-DTPA, as well as other chelates, accumulates in areas of ischaemia; therefore after the local release from liposomes the radiotracer remains associated with the lesion. A similar finding has been reported in ischaemic intestine (Palmer et al, 1981).…”
“…99mTc-DTPA, as well as other chelates, accumulates in areas of ischaemia; therefore after the local release from liposomes the radiotracer remains associated with the lesion. A similar finding has been reported in ischaemic intestine (Palmer et al, 1981).…”
“…Some of the earliest studies achieved this by simply encapsulating a radiometal complex with DTPA inside the liposomal core during formation of the liposomes (see Section 4.2.2). This was first done with 99m Tc, [275][276][277][278] and later with 111 In 279 and 159 Gd-DTPA, 280 as well as encapsulating the DOTA complex of 225 Ac. 281 One drawback of this method is the longer, more complicated radiosynthesis needed (especially relevant when using short-lived isotopes).…”
Section: Radiolabelling Of Organic Nanomaterialsmentioning
This review describes and critically evaluates the various strategies available to radiolabel organic and inorganic nanomaterials for in vivo imaging and therapy
“…Some of the earliest studies performing the radiolabelling of liposomes achieved this by simply encapsulating a radiometal complex with DTPA inside the liposomal core during formation of the liposomes. This was first done with 99m Tc [[96], [97], [98], [99]], and later 111 In [100] and 159 Gd-DTPA [101] – as well as with the therapeutic isotope 225 Ac by encapsulating the DOTA complex [102]. Alternatively, encapsulated drugs could themselves be labelled with radioiodine [56,[103], [104], [105], [106], [107], [108], [109]] or 18 F [110] before liposomal formulation and more recently liposomes were radiolabelled by being prepared in the presence of [ 18 F]FDG [[111], [112], [113], [114]].…”
The integration of nuclear imaging with nanomedicine is a powerful tool for efficient development and clinical translation of liposomal drug delivery systems. Furthermore, it may allow highly efficient imaging-guided personalised treatments. In this article, we critically review methods available for radiolabelling liposomes. We discuss the influence that the radiolabelling methods can have on their biodistribution and highlight the often-overlooked possibility of misinterpretation of results due to decomposition in vivo. We stress the need for knowing the biodistribution/pharmacokinetics of both the radiolabelled liposomal components and free radionuclides in order to confidently evaluate the images, as they often share excretion pathways with intact liposomes (e.g. phospholipids, metallic radionuclides) and even show significant tumour uptake by themselves (e.g. some radionuclides). Finally, we describe preclinical and clinical studies using radiolabelled liposomes and discuss their impact in supporting liposomal drug development and clinical translation in several diseases, including personalised nanomedicine approaches.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.